Olanzapine pamoate - Blockbuster or damp squib?

International Journal of Clinical Practice

Volumn 63, Issue 4, 2009, Pages 540-541

  Taylor, D M ^a,b  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; RISPERIDONE;

CONFUSION; DELIRIUM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG STORAGE; DRUG TOLERABILITY; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEDATION; SHORT SURVEY; SIDE EFFECT;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; HUMANS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 62549140073     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02016.x     Document Type: Short Survey

References (10)

1. Citrome L. Olanzapine pamoate: a stick in time? Int J Clin Pract 2009 63 : 140 50.
2. Leucht S, Corves C, Arbter D et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009 373 : 31 41.
3. Leucht S, Komossa K, Rummel-Kluge C et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009 166 : 152 63.
4. Taylor DM, McAskill R. Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatr Scand 2000 101 : 416 32.
5. Mir S, Taylor D. Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol 2001 16 : 63 74.
6. Taylor D, Fischetti C, Sparshatt A et al. Risperidone long-acting injection: a prospective 3 year analysis of its use in clinical practice. J Clin Psychiatry 2008 [Epub ahead of print].
7. Young CL, Taylor DM. Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatr Scand 2006 114 : 14 20.
8. Eerdekens M, Van H I, Remmerie B et al. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 2004 70 : 91 100.
9. Kinon BJ, Volavka J, Stauffer V et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol 2008 28 : 392 400.
10. FDA. Psychopharmacologic Drugs Advisory Committee Briefing Document - Zyprexa Olanzapine Pamoate (Op) Depot, 2008. http://www.fda.gov (accessed 18 December 2008).